Leptin therapy in type 2 diabetes
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
There is a pressing need for new effective therapeutic strategies for addressing the epidemic of type 2 diabetes. Leptin has been shown to reduce hyperglycaemia in rodent models of type 1 diabetes and has recently been shown to normalize fasting plasma glucose concentrations in a rodent model of polygenic obesity and type 2 diabetes. Overall, these findings suggest that leptin may be an effective therapeutic option for both type 1 and type 2 diabetes. However, short‐term human clinical studies in overweight and obese patients with recently diagnosed type 2 diabetes have reported minimal efficacy of leptin administration to lower blood glucose levels. Herein, the role of leptin in the maintenance of glucose homeostasis and the potential use of leptin in the treatment of type 2 diabetes are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Elmquist, J. K., Elias, C. F., & Saper, C. B. (1999) · Neuron · doi:10.1016/s0896-6273(00)81084-3 · Cited by 1,160
OBESE, A NEW MUTATION IN THE HOUSE MOUSE*
INGALLS, A. M., DICKIE, M. M., & SNELL, G. D. (1950) · Journal of Heredity · doi:10.1093/oxfordjournals.jhered.a106073 · Cited by 1,090
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038 · cited 1×
“Similarly, studies of leptin replacement therapy in lipodystrophic patients report improvements of insulin sensitivity with coinciding decreases of hepatic lipid deposition [25,26].”
BackgroundDiabetes, a New Mutation in the Mouse
Hummel, K. P., Dickie, M. M., & Coleman, D. L. (1966) · Science · doi:10.1126/science.153.3740.1127 · Cited by 990
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 2×
“Similarly, studies of leptin replacement therapy in lipodystrophic patients report improvements of insulin sensitivity with coinciding decreases of hepatic lipid deposition [25,26].”
BackgroundEffects of parabiosis of obese with diabetes and normal mice.
Coleman, D. L. (1973) · Diabetologia · doi:10.1007/bf01221857 · Cited by 729 · cited 1×
“For example, parabiosis of an ob/ob mouse to a wild-type mouse results in marked reductions of food intake and body weight in the wild-type mouse and marked improvements of hyperglycaemia in the ob/ob mouse [11].”
BackgroundGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670 · cited 1×
“These findings suggest that glucagon is potentially an efficacious target for the treatment of diabetes [45], which is supported by the finding that the glucagon receptor knockout mouse is resistant to developing diabetes [46].”
BackgroundLicinio, J., Caglayan, S., Ozata, M., Yildiz, B. O., de Miranda, P. B., O'Kirwan, F., Whitby, R., Liang, L., Cohen, P., Bhasin, S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308767101 · Cited by 505
Coppari, R., Ichinose, M., Lee, C. E., Pullen, A. E., Kenny, C. D., McGovern, R. A., Tang, V., Liu, S. M., Ludwig, T., Chua, S. C., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.004 · Cited by 457
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Leptin and the Central Nervous System Control of Glucose Metabolism
Morton, G. J., & Schwartz, M. W. (2011) · Physiological Reviews · doi:10.1152/physrev.00007.2010 · Cited by 338 · cited 3×
“Furthermore, leptin has been suggested to exert important glucoregulatory and insulin-sensitizing effects through central signalling pathways [6,14,33,37,38].”
BackgroundGlucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327
Morton, G. J., Gelling, R. W., Niswender, K. D., Morrison, C. D., Rhodes, C. J., & Schwartz, M. W. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.10.009 · Cited by 292
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 3×
“Leptin administration to ob/ob mice has been shown to increase IGFBP2 signalling, and overexpression of IGFBP2 by an adenovirus reverses diabetes and improves hepatic insulin sensitivity in ob/ob, Ay/a, dietinduced obese and streptozotocin-treated mice [19].”
BackgroundLeptin-Dependent Control of Glucose Balance and Locomotor Activity by POMC Neurons
Huo, L., Gamber, K., Greeley, S., Silva, J., Huntoon, N., Leng, X.-H., & Bjørbæk, C. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.05.003 · Cited by 226 · cited 2×
“Several previous studies have shown that reactivation of leptin receptor signalling in various rodent models with a monogenetic defect of the leptin receptor and consequent obesity and type 2 diabetes improves glucose and lipid metabolism [6,39,47].”
Making insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219
Havel, P. J., Uriu-Hare, J. Y., Liu, T., Stanhope, K. L., Stern, J. S., Keen, C. L., & Ahrén, B. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.5.r1482 · Cited by 198
Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat.
Chinookoswong, N., Wang, J. L., & Shi, Z. Q. (1999) · Diabetes · doi:10.2337/diabetes.48.7.1487 · Cited by 197
German, J. P., Thaler, J. P., Wisse, B. E., Oh-I, S., Sarruf, D. A., Matsen, M. E., Fischer, J. D., Taborsky, G. J., Schwartz, M. W., & Morton, G. J. (2011) · Endocrinology · doi:10.1210/en.2010-0890 · Cited by 169 · cited 1×
“Furthermore, leptin has been suggested to exert important glucoregulatory and insulin-sensitizing effects through central signalling pathways [6,14,33,37,38].”
BackgroundGerman, J., Kim, F., Schwartz, G. J., Havel, P. J., Rhodes, C. J., Schwartz, M. W., & Morton, G. J. (2009) · Endocrinology · doi:10.1210/en.2009-0445 · Cited by 164 · cited 1×
“Nevertheless, reductions of circulating glucagon concentrations with leptin administration in models of type 1 and type 2 diabetes are associated with reductions of hepatic gluconeogenic gene expression [5,37,40,44].”
BackgroundLeptin Deficiency Causes Insulin Resistance Induced by Uncontrolled Diabetes
German, J. P., Wisse, B. E., Thaler, J. P., Oh-I, S., Sarruf, D. A., Ogimoto, K., Kaiyala, K. J., Fischer, J. D., Matsen, M. E., Taborsky, G. J., et al. (2010) · Diabetes · doi:10.2337/db09-1918 · Cited by 159
Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156 · cited 1×
“[58] showed that long-acting PEGylated leptin given in combination with exendin-4 or fibroblast growth factor 21 (FGF21) results in an enhancement of body weight loss greater than that observed with exendin-4 or FGF21 alone.”
Hidaka, S., Yoshimatsu, H., Kondou, S., Tsuruta, Y., Oka, K., Noguchi, H., Okamoto, K., Sakino, H., Teshima, Y., Okeda, T., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0164com · Cited by 108
Cited by
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“Leptin and gut-derived hormones have been studied in the search for therapeutic targets for the treatment of obesity, but these attempts were not successful (Crawley & Beinfeld 1983, Jordan et al. 2008, Costantini et al. 2011, Moon et al. 2011, Cummings 2013), except for GLP-1RA.”
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Modulation of glucose metabolism by the renin-angiotensin-aldosterone system
Favre, G. A., Esnault, V. L. M., & Van Obberghen, E. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2014 · Cited by 114
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Drent, M. L., Diamant, M., & IJzerman, R. G. (2016) · Diabetes Care · doi:10.2337/dc15-0772 · Cited by 102
Metadata
- Authors
- Cummings, B. P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-01-21
- Volume
- 15
- Issue
- 7
- Pages
- 607-612
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1988740767
- Cited by
- 23
- References
- 24
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.